Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma

The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer

NCT02809898 ·Status: UNKNOWN

Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC Recurrence

NCT04506398 ·Status: UNKNOWN

The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma

NCT06750159 ·Status: NOT_YET_RECRUITING

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing

NCT05520788 ·Status: RECRUITING

Circulating Tumor Cell Capture for Early Diagnosis and Postoperative Tumor Recurrence Monitoring of Liver Cancer

NCT04688606 ·Status: UNKNOWN

Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma

NCT05626985 ·Status: RECRUITING

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

NCT05292443 ·Status: WITHDRAWN

Primary Hepatobiliary Cancer Cohort of Central China

NCT05520801 ·Status: RECRUITING

Recurrent Liver Cancer: Reconceptualization and Reevaluation

NCT06430983 ·Status: RECRUITING

A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data

NCT07156617 ·Status: NOT_YET_RECRUITING

Lenvatinib Therapy in HCC Patients After LDLT

NCT05572528 ·Status: RECRUITING

The Utility of Cell-free DNA Methylation Markers for Hepatocellular Carcinoma

NCT05573217 ·Status: UNKNOWN

Construction of a Recurrence Risk Prediction Model for Liver Resection Based on Drug Sensitivity of Patient-derived Hepatocellular Carcinoma Organoid

NCT06699524 ·Status: ACTIVE_NOT_RECRUITING

Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma

NCT06272656 ·Status: RECRUITING

Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

NCT06818097 ·Status: COMPLETED

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

NCT05621499 ·Status: NOT_YET_RECRUITING ·Phase: NA

Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System

NCT02525952 ·Status: UNKNOWN ·Phase: NA

HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Patients At High Risk of Recurrence

NCT06812039 ·Status: RECRUITING ·Phase: PHASE2

Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy

NCT03039062 ·Status: UNKNOWN

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

NCT06904014 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery

NCT06762782 ·Status: RECRUITING ·Phase: PHASE2

The Value of 68Ga-FAPI PET/CT in the Efficacy Evaluation of Advanced Unresectable Hepatocellular Carcinoma Patients Undergoing Systemic Antitumor Therapy

NCT06746194 ·Status: RECRUITING

Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma

NCT05759858 ·Status: RECRUITING

Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver Tumors

NCT06588569 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension

NCT06280313 ·Status: RECRUITING